Download PDF
Horm Metab Res 2022; 54(07): 442-449
DOI: 10.1055/a-1861-2475
Original Article: Endocrine Care

Correlation of Serum Estradiol with Bone Mineral Density and Bone Metabolism in Patients of Postmenopausal Type 2 Diabetes Mellitus Complicated with Osteoporosis

Fan Yang
1   Department of Endocrinology, the Affiliated Wuxi No.2 People’s Hospital of Nanjing Medical University, Wuxi 214002, Jiangsu, China
,
Qiangwei Xu
2   Department of Rheumatology, the Affiliated Wuxi No. 2 People’s Hospital of Nanjing Medical University, Wuxi 214002, Jiangsu, China
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Type 2 diabetes mellitus (T2DM) complicated with osteoporosis, is a systemic metabolic disease that affects postmenopausal women. This disease is closely related to the lack of estrogen. This study aims to demonstrate the correlation between serum estradiol (E2) levels and osteoporosis, bone mineral density, and bone metabolism indicators in postmenopausal women with T2DM complicated with osteoporosis (T2DM-OP). 130 postmenopausal women with T2DM were divided into the T2DM group (n=62) and the T2DM-OP group (n=68) according to bone mineral density (BMD). In addition, 80 postmenopausal women with average blood glucose and bone density were selected as the healthy control group. We compare the serum levels of E2, bone metabolism indicators, and biochemistry indexes among the three groups of participants. Compared with the healthy control and T2DM groups, the BMD and serum level of E2 in T2DM-OP patients were significantly decreased, while the serum levels of bone alkaline phosphatase, type I procollagen amino-terminal propeptide, osteocalcin, and β-collagen C-terminal collagen cross-links were significantly increased. The serum levels of E2 in the postmenopausal T2DM-OP patients are positively correlated with BMD and negatively correlated with bone resorption indicators.

bone metabolism - bone mineral density - estradiol, postmenopausal type 2 diabetes mellitus - osteoporosis


Publication History

Received: 16 February 2022

Accepted after revision: 16 May 2022

Article published online:
14 July 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Zamani M, Zamani V, Heidari B. et al. Prevalence of osteoporosis with the World Health Organization diagnostic criteria in the Eastern Mediterranean Region: a systematic review and meta-analysis. Arch Osteoporos 2018; 13: 129
    CrossrefPubMedGoogle Scholar
  • 2 Tella SH, Gallagher JC. Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol 2014; 142: 155-170
    CrossrefPubMedGoogle Scholar
  • 3 Black DM, Rosen CJ. Clinical practice. Postmenopausal osteoporosis. N Engl J Med 2016; 374: 254-262
    CrossrefPubMedGoogle Scholar
  • 4 Svedbom A, Hernlund E, Ivergard M. et al. Osteoporosis in the European Union: a compendium of country-specific reports. Arch Osteoporos 2013; 8: 137
    CrossrefPubMedGoogle Scholar
  • 5 Lu YC, Lin YC, Lin YK. et al. Prevalence of osteoporosis and low bone mass in older Chinese population based on bone mineral density at multiple skeletal sites. Sci Rep 2016; 6: 25206
    CrossrefPubMedGoogle Scholar
  • 6 Kung AW, Fan T, Xu L. et al. Factors influencing diagnosis and treatment of osteoporosis after a fragility fracture among postmenopausal women in Asian countries: a retrospective study. BMC Womens Health 2013; 13: 7
    CrossrefPubMedGoogle Scholar
  • 7 Fu C, Shi R.. Osteoclast biology in bone resorption: a review. STEMedicine 2020; 1: e57
    CrossrefPubMedGoogle Scholar
  • 8 de L, van der Klift M, de Laet CE. et al. Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study. Osteoporos Int 2005; 16: 1713-1720
    CrossrefPubMedGoogle Scholar
  • 9 Xia JW, Tan SJ, Zhang XL. et al. Correlation of serum testosterone with insulin resistance in elderly male type 2 diabetes mellitus patients with osteoporosis. J Diabetes Investig 2015; 6: 548-552
    CrossrefPubMedGoogle Scholar
  • 10 Ardawi MS, Rouzi AA, Al-Sibiani SA. et al. High serum sclerostin predicts the occurrence of osteoporotic fractures in postmenopausal women: the Center of Excellence for Osteoporosis Research Study. J Bone Miner Res 2012; 27: 2592-2602
    CrossrefPubMedGoogle Scholar
  • 11 Chung YS, Chung DJ, Kang MI. et al. Vitamin D repletion in Korean postmenopausal women with osteoporosis. Yonsei Med J 2016; 57: 923-927
    CrossrefPubMedGoogle Scholar
  • 12 Abdi H, Hosseinpanah F, Azizi F. et al. Screening for dysglycemia: a comment on classification and diagnosis of diabetes in American diabetes association standards of medical care in diabetes-2016. Arch Iran Med 2017; 20: 389
    PubMedGoogle Scholar
  • 13 Kalimeri M, Leek F, Wang NX. et al. Folate and vitamin B-12 status is associated with bone mineral density and hip strength of postmenopausal Chinese-Singaporean women. JBMR Plus 2020; 4: e10399
    CrossrefPubMedGoogle Scholar
  • 14 Farr JN, Khosla S. Determinants of bone strength and quality in diabetes mellitus in humans. Bone 2016; 82: 28-34
    CrossrefPubMedGoogle Scholar
  • 15 Park SY, Ahn SH, Yoo JI. et al. Clinical application of bone turnover markers in osteoporosis in Korea. J Bone Metab 2019; 26: 19-24
    CrossrefPubMedGoogle Scholar
  • 16 de Waard EA, van Geel TA, Savelberg HH. et al. Increased fracture risk in patients with type 2 diabetes mellitus: an overview of the underlying mechanisms and the usefulness of imaging modalities and fracture risk assessment tools. Maturitas 2014; 79: 265-274
    CrossrefPubMedGoogle Scholar
  • 17 Poiana C, Capatina C.. Fracture risk assessment in patients with diabetes mellitus. J Clin Densitom 2017; 20: 432-443
    CrossrefPubMedGoogle Scholar
  • 18 Napoli N, Chandran M, Pierroz DD. et al. Mechanisms of diabetes mellitus-induced bone fragility. Nat Rev Endocrinol 2017; 13: 208-219
    CrossrefPubMedGoogle Scholar
  • 19 Miyake H, Kanazawa I, Sugimoto T. Association of bone mineral density, bone turnover markers, and vertebral fractures with all-cause mortality in type 2 diabetes mellitus. Calcif Tissue Int 2018; 102: 1-13
    CrossrefPubMedGoogle Scholar
  • 20 Jang M, Kim H, Lea S. et al. Effect of duration of diabetes on bone mineral density: a population study on East Asian males. BMC Endocr Disord 2018; 18: 61–70
    CrossrefPubMedGoogle Scholar
  • 21 Leidig-Bruckner G, Grobholz S, Bruckner T. et al. Prevalence and determinants of osteoporosis in patients with type 1 and type 2 diabetes mellitus. BMC Endocr Disord 2014; 14: 33
    CrossrefPubMedGoogle Scholar
  • 22 Ma L, Oei L, Jiang L. et al. Association between bone mineral density and type 2 diabetes mellitus: a meta-analysis of observational studies. Eur J Epidemiol 2012; 27: 319-332
    CrossrefPubMedGoogle Scholar
  • 23 Afshinnia F, Chacko S, Zahedi T. Association of lower serum cholesterol levels with higher risk of osteoporosis in type 2 diabetes. Endocr Pract 2007; 13: 620-628
    CrossrefPubMedGoogle Scholar
  • 24 Ettinger MP. Aging bone and osteoporosis: strategies for preventing fractures in the elderly. Arch Intern Med 2003; 163: 2237-2246
    CrossrefPubMedGoogle Scholar
  • 25 Moberg L, Nilsson PM, Samsioe G. et al. Low androstenedione/sex hormone binding globulin ratio increases fracture risk in postmenopausal women. The women's health in the Lund area study. Maturitas 2013; 75: 270-275
    CrossrefPubMedGoogle Scholar
  • 26 Ran C, Xiaojuan X, Wenxue G. et al. Sexual dimorphism in the relation between sex hormones and osteoporosis in patients with type 2 diabetes mellitus. J Bone Miner Metab 2022; 40: 460-467
    CrossrefPubMedGoogle Scholar
  • 27 Kanda J, Furukawa M, Izumo N. et al. Effects of the linagliptin, dipeptidyl peptidase-4 inhibitor, on bone fragility induced by type 2 diabetes mellitus in obese mice. Drug Discov Ther 2020; 14: 218-225
    CrossrefPubMedGoogle Scholar
  • 28 Purnamasari D, Puspitasari MD, Setiyohadi B. et al. Low bone turnover in premenopausal women with type 2 diabetes mellitus as an early process of diabetes-associated bone alterations: a cross-sectional study. BMC Endocr Disord 2017; 17: 72
    CrossrefPubMedGoogle Scholar
  • 29 Picke AK, Campbell G, Napoli N. et al. Update on the impact of type 2 diabetes mellitus on bone metabolism and material properties. Endocr Connect 2019; 8: R55-R70
    CrossrefPubMedGoogle Scholar
  • 30 Szeliga A, Maciejewska-Jeske M, Meczekalski B.. Bone health and evaluation of bone mineral density in patients with premature ovarian insufficiency. Prz Menopauzalny 2018; 17: 112-116
    PubMedGoogle Scholar
  • 31 Snyder PJ, Kopperdahl DL, Stephens-Shields AJ. et al. Effect of testosterone treatment on volumetric bone density and strength in older men with low testosterone: a controlled clinical trial. JAMA Intern Med 2017; 177: 471-479
    CrossrefPubMedGoogle Scholar
  • 32 Han K, Yun YM, Moon SG. et al. Bone mineral density and serum 25-hydroxyvitamin D in subtypes of idiopathic benign paroxysmal positional vertigo. Am J Otolaryngol 2020; 41: 102313
    CrossrefPubMedGoogle Scholar
  • 33 Zhang B, Zhao W, Tu J. et al. The relationship between serum 25-hydroxyvitamin D concentration and type 2 diabetic peripheral neuropathy: A systematic review and a meta-analysis. Medicine (Baltimore) 2019; 98: e18118
    CrossrefPubMedGoogle Scholar
  • 34 Ouyang X, Ding Y, Yu L. et al. Comparison of the clinical effect of DHS and PFNA on senile osteoporotic fracture and their significance of changes in BALP expression level. J Musculoskelet Neuronal Interact 2020; 20: 556-562
    PubMedGoogle Scholar
  • 35 Lertwanakarn T, Suntravat M, Sanchez EE. et al. Suppression of cardiomyocyte functions by beta-CTX isolated from the Thai king cobra (Ophiophagus hannah) venom via an alternative method. J Venom Anim Toxins Incl Trop Dis 2020; 26: e20200005
    CrossrefPubMedGoogle Scholar
  • 36 Bhattoa HP, Cavalier E, Eastell R. et al. Analytical considerations and plans to standardize or harmonize assays for the reference bone turnover markers PINP and beta-CTX in blood. Clin Chim Acta 2021; 515: 16-20
    CrossrefPubMedGoogle Scholar
  • 37 Shetty S, Kapoor N, Bondu JD. et al. Bone turnover markers: Emerging tool in the management of osteoporosis. Indian J Endocrinol Metab 2016; 20: 846-852
    CrossrefPubMedGoogle Scholar
  • 38 Stern A, Laughlin GA, Bergstrom J. et al. The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappaB legend with bone mineral density in older adults: the Rancho Bernardo study. Eur J Endocrinol 2007; 156: 555-562
    CrossrefPubMedGoogle Scholar
  • 39 Fatchiyah F, Setiawan B, Sasase T. et al. The amelioration of T2DM rat femoral bone achieved by anti-osteoporosis of caprine CSN1S2 protein through bone morphogenetic protein signaling pathway. Acta Biochim Pol 2021; 68: 265-275
    PubMedGoogle Scholar
  • 40 Wang X, Jiang L, Shao X. Association analysis of insulin resistance and osteoporosis risk in Chinese patients with T2DM. Ther Clin Risk Manag 2021; 17: 909-916
    CrossrefPubMedGoogle Scholar